Developer docs
API playgroundTry for free, no card

Search company profiles

AEYE Health

Full company profile

uuid00007sy

Namestring
AEYE Health
Legal namestring
AEYE Health, Inc.
Websiteurl
aeyehealth.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

AEYE Health is a US-based digital health company founded in 2019 in New York City that has built AEYE-DS, an FDA-cleared fully autonomous AI diagnostic screening solution for diabetic retinopathy. The technology applies deep learning algorithms to single non-mydriatic retinal fundus images, delivering a diagnostic result in under one minute with AI processing in under five seconds, without requiring specialist over-read or pupil dilation. AEYE-DS is offered in two hardware configurations — Aurora AEYE on the Optomed portable handheld camera (FDA-cleared May 2024, the first fully autonomous AI approved for portable use) and a tabletop configuration on the Topcon NW400/NW500 — and achieves 92-93% sensitivity, 89-94% specificity, and >99% imageability per Phase III pivotal studies.

The company's product portfolio also includes AEYE-X, an investigational platform that analyzes retinal images to detect or predict 100+ systemic and ocular conditions across four diagnostic pillars (chronic ocular disease, systemic health, cognitive health, and vision/refractive assessment); AEYE-X is not sold in the US. A February 2026 BMJ Innovations publication demonstrated that the company's deep learning technology can estimate both systolic and diastolic blood pressure from a single retinal image, validated against 100,000+ UK Biobank images.

AEYE Health operates on an all-inclusive SaaS subscription model with no upfront capital investment, with Limited and Unlimited tiers aligned to predictable-volume practices and high-volume health systems respectively. The solution integrates with Epic and other major EHRs for automated ordering, result delivery, care gap reporting, and billing under CPT 92229 (~$50 Medicare national average / up to $100 from private insurers per exam in 2026), with practices retaining 100% of reimbursement. Go-to-market combines enterprise field sales into health systems and IDNs, inside sales for mid-market primary care and endocrinology clinics, event-driven demand generation at ADA/ACD/FMX conferences, and a channel partnership with Ford Medical for pharmacy distribution. Named customers include UMass Memorial Health and Bethesda Health Clinic.

Short descriptiontext

AEYE Health is a US digital health company that markets AEYE-DS, an FDA-cleared fully autonomous AI for diabetic retinopathy screening using a single retinal image per eye, deployed via SaaS subscription into primary care, endocrinology, teleretinal, pharmacy, and rural clinic settings.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI retinal screening, diabetic retinopathy detection, autonomous diagnostic AI, medical imaging software, clinical decision support
Industry3 codes
PRIMARYHLAHAJAB
Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAKAKAN
Ocular Imaging & Diagnostic Testing Centers
NAICS code1 code
  • Diagnostic Imaging Centers621512
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Services-Medical Laboratories8071
Product category
AI Medical Diagnostics
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1AEYE-DS SaaS Subscription
TypeSubscription Recurring
Description

All-inclusive Software as a Service (SaaS) subscription model requiring no upfront capital investment. The subscription covers the indicated retinal camera, EHR integration, and software updates with no hidden charges. Two subscription tiers: Limited (tailored for practices with specific/predictable patient volumes) and Unlimited (for high-volume health systems maximizing screening reach without per-patient constraints). Revenue is generated through recurring subscription fees billed on a per-encounter or tiered basis, complemented by CPT 92229 reimbursements retained entirely by the practice.

aeyehealth.com
2CPT 92229 Reimbursement
TypeTransaction Fee
Description

Autonomous AI retinal analysis is billed under CPT 92229, a dedicated point-of-care autonomous retinal analysis code fully reimbursable across Medicare, Medicaid, and private insurance. For 2026, Medicare national average reimbursement is approximately $50 per exam; private insurers frequently reimburse up to $100 per exam. Practices retain 100% of reimbursement when billing AEYE-DS under CPT 92229 because the AI performs the diagnostic analysis autonomously, eliminating the need for specialist over-reads or fee-splitting.

aeyehealth.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure, Supply Chain
Pricing details3 tiers
1Limited Subscription - for practices with specific or predictable patient volumes
ModelSubscriptionBilling cadenceMulti-year contract
Notes

All-inclusive SaaS covering camera, EHR integration, and software updates. No upfront capital investment required. Tier designed for practices with predictable screening volumes.

aeyehealth.com
2Unlimited Subscription - for high-volume health systems
ModelSubscriptionBilling cadenceMulti-year contract
Notes

All-inclusive SaaS covering camera, EHR integration, and software updates. No per-patient constraints for high-volume health systems maximizing screening reach.

aeyehealth.com
3CPT 92229 Reimbursement (per exam)
ModelTransaction based/ take rateBilling cadencePay-as-you-go
Notes

Medicare national average ~$50 per exam (2026). Private insurers frequently reimburse up to $100 per exam. Practices retain 100% of reimbursement.

aeyehealth.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 3 records shown
1AEYE-DS
Description

FDA-cleared autonomous AI diagnostic screening solution for diabetic retinopathy screening using portable and tabletop retinal cameras.

aeyehealth.com
+2 more records
Core offering1 text field

AEYE Health develops and sells FDA-cleared autonomous AI software (AEYE-DS) that analyzes retinal fundus images to screen for diabetic retinopathy at the point of care, delivering diagnostic results in under one minute without requiring specialist interpretation. The all-inclusive SaaS subscription bundles the AI software, compatible retinal cameras (portable Optomed Aurora or tabletop Topcon NW400), and EHR/EMR integration, enabling primary care providers, endocrinologists, health systems, and pharmacies to perform reimbursable DR screening (CPT 92229) during routine visits. The investigational AEYE-X platform extends the technology to comprehensive screening for over 100 ocular and systemic conditions from a single retinal image.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

AEYE Health offers a dual-product portfolio centered on AI-powered retinal imaging diagnostics. AEYE-DS is the FDA-cleared core product for autonomous diabetic retinopathy screening, available in two configurations: portable (Optomed Aurora) and tabletop (Topcon NW400). AEYE-X is an investigational comprehensive screening platform extending the technology to detect and predict over 100 systemic and ocular conditions from retinal images. Both products use deep learning to analyze retinal images, deliver results in under one minute at point of care, and require only one image per eye with no dilation.

Product and service2 records
1AEYE-DS
CategoryAutonomous AI Diagnostic Screening
Description

FDA-cleared fully autonomous AI diagnostic screening solution for point-of-care detection of more-than-mild diabetic retinopathy (mtmDR) in adults diagnosed with diabetes. Uses a single non-mydriatic retinal image per eye with no dilation required, available in portable handheld (Optomed Aurora, 92-93% sensitivity, 89-94% specificity) and tabletop (Topcon NW400, 93% sensitivity, 91% specificity) configurations. Delivers diagnostic results in under one minute with AI processing under 5 seconds, achieves >99% imageability, requires no physician interpretation, and is reimbursable under CPT 92229. Integrates with Epic and other EHRs for automated ordering, result delivery, billing, and care gap reporting.

2AEYE-X
CategoryAI Comprehensive Health Screening Platform
Description

Investigational AI-based comprehensive screening platform for detecting or predicting over 100 conditions from single retinal images per eye. Analyzes ocular diseases (diabetic retinopathy, glaucoma, AMD, retinal occlusions, cataract, diabetic macular edema), systemic health (cardiovascular disease, hypertension, diabetes, CKD), cognitive health (dementia risk), and vision/refractive assessment using deep learning algorithms. Camera-agnostic, delivers results in under one minute. Includes predictive blood pressure estimation capability validated against the UK Biobank. Not sold in the US; available for investigational use only.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-01-01
Description

AEYE Health expanded its nationwide integration of AEYE-DS with Epic Systems' electronic medical record platform, enabling healthcare providers to order and receive diabetic retinopathy screening results in under 1 minute directly within their existing Epic clinical workflows. The integration supports automated billing under CPT 92229, care gap reporting, and automated referral triggers for positive cases. This partnership is described as one of the first-ever AI-specific reimbursement integrations in healthcare.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-07-01
Description

AEYE Health partnered with Ford Medical in July 2025 to distribute AI-based retinal imaging screening solutions across US pharmacies. This partnership enables pharmacy-based point-of-care diabetic retinopathy screening, extending AEYE Health's reach into community retail health settings and expanding access to screening for underserved populations.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-04-01
Description

AEYE Health partnered with Topcon Healthcare to integrate its autonomous diabetic retinopathy screening AI into the Topcon NW500 fundus camera (announced April 2025). This enables the Topcon NW500 to deliver AEYE-DS's autonomous AI diagnostic results at the point of care, expanding the hardware ecosystem compatible with AEYE-DS.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-06-01
Description

AEYE Health and Optomed partnered to launch Aurora AEYE, the first FDA-cleared portable AI-powered diabetic retinopathy screening solution providing on-the-spot diagnosis. Optomed provides the Aurora handheld retinal camera; AEYE Health provides the autonomous AI diagnostic software. This partnership resulted in the first-ever FDA clearance for a fully autonomous AI for portable diabetic retinopathy screening (May 2024).

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Digital Diagnostics developed IDx-DR, the first FDA-cleared fully autonomous AI for diabetic retinopathy screening. It is the most direct head-to-head competitor to AEYE-DS in US primary care, sharing the autonomous, non-mydriatic, single-image-per-eye workflow and targeting the same CPT 92229 reimbursement code.

TypeDirect peer
Description

Eyenovia acquired the EyeArt AI-based diabetic retinopathy screening system, one of the most widely deployed autonomous DR screening platforms globally. EyeArt competes with AEYE-DS for primary care, endocrinology, and teleretinal screening contracts, and Eyenovia's deeper commercial footprint makes it a key benchmark for AEYE's enterprise sales motion.

TypeBroad incumbent
Description

Topcon is a global ophthalmic device incumbent whose NW400 and NW500 fundus cameras are integrated with AEYE-DS. As a hardware partner, Topcon is a route to market, but it also develops its own screening software ecosystem and Harmony RS (retinal data management), making it both a collaborator and a potential competitor in integrated DR screening.

TypeEmerging player
Description

Optomed is the maker of the Aurora handheld retinal camera, which AEYE-DS is integrated with to produce the only FDA-cleared portable autonomous DR screening solution. Optomed also sells its own AI screening software and competes in the portable fundus camera category, making it a strategic partner with overlapping commercial interests.

TypeDirect peer
Description

IRIS operates a teleretinal screening service used by health systems and primary care clinics, and integrated AEYE-DS into its platform in 2023. IRIS is both a distribution partner and a competitor whose legacy human-reader workflow is being displaced by autonomous AI, making it a closely comparable teleretinal service peer.

TypeEmerging player
Description

RetinAI Medical (now Ikerian) develops AI platforms for retinal image analysis covering diabetic retinopathy, AMD, and glaucoma, with both pharma research and clinical screening use cases. It is an emerging peer to AEYE-X's multi-condition screening thesis and competes in the broader ophthalmic AI analytics category.

7Nanox (Zebra Medical Vision)
TypeBroad incumbent
Description

Nanox acquired Zebra Medical Vision, an AI medical imaging company that analyzes radiology images to detect multiple conditions. While focused on radiology rather than retinal screening, Zebra/Nanox is a comparable medical imaging AI platform peer with a similar multi-condition, AI-driven diagnostic ambition to AEYE-X.

TypeBroad incumbent
Description

VoxelCloud is a medical imaging AI company providing diagnostic AI solutions across ophthalmology, radiology, and pathology. It is comparable to AEYE Health as a medical imaging AI vendor, with overlap in ophthalmic disease detection from imaging data, and serves as a broad-incumbent reference point for AI clinical screening scale-up.

TypeOthers
Description

Arterys (now Tempus) provides cloud-native AI medical imaging platforms deployed in clinical workflows. It is an adjacent AI imaging infrastructure peer rather than a direct competitor, but is relevant context for AEYE's positioning of AI diagnostics integrated directly into clinical workflow and reporting.

10Sight Diagnostics
TypeEmerging player
Description

Sight Diagnostics applies computer vision and AI to blood and retinal analysis, with FDA-cleared products for point-of-care diagnostics. Its combination of AI imaging diagnostics and decentralised point-of-care deployment is conceptually similar to AEYE's portable, single-image autonomous screening model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AEYE Health

AI Medical Diagnosticsaeyehealth.com

AEYE Health is a US digital health company that markets AEYE-DS, an FDA-cleared fully autonomous AI for diabetic retinopathy screening using a single retinal image per eye, deployed via SaaS subscription into primary care, endocrinology, teleretinal, pharmacy, and rural clinic settings.

What AEYE Health does

AEYE Health is a US-based digital health company founded in 2019 in New York City that has built AEYE-DS, an FDA-cleared fully autonomous AI diagnostic screening solution for diabetic retinopathy. The technology applies deep learning algorithms to single non-mydriatic retinal fundus images, delivering a diagnostic result in under one minute with AI processing in under five seconds, without requiring specialist over-read or pupil dilation. AEYE-DS is offered in two hardware configurations — Aurora AEYE on the Optomed portable handheld camera (FDA-cleared May 2024, the first fully autonomous AI approved for portable use) and a tabletop configuration on the Topcon NW400/NW500 — and achieves 92-93% sensitivity, 89-94% specificity, and >99% imageability per Phase III pivotal studies.

The company's product portfolio also includes AEYE-X, an investigational platform that analyzes retinal images to detect or predict 100+ systemic and ocular conditions across four diagnostic pillars (chronic ocular disease, systemic health, cognitive health, and vision/refractive assessment); AEYE-X is not sold in the US. A February 2026 BMJ Innovations publication demonstrated that the company's deep learning technology can estimate both systolic and diastolic blood pressure from a single retinal image, validated against 100,000+ UK Biobank images.

AEYE Health operates on an all-inclusive SaaS subscription model with no upfront capital investment, with Limited and Unlimited tiers aligned to predictable-volume practices and high-volume health systems respectively. The solution integrates with Epic and other major EHRs for automated ordering, result delivery, care gap reporting, and billing under CPT 92229 (~$50 Medicare national average / up to $100 from private insurers per exam in 2026), with practices retaining 100% of reimbursement. Go-to-market combines enterprise field sales into health systems and IDNs, inside sales for mid-market primary care and endocrinology clinics, event-driven demand generation at ADA/ACD/FMX conferences, and a channel partnership with Ford Medical for pharmacy distribution. Named customers include UMass Memorial Health and Bethesda Health Clinic.

AEYE Health firmographics

Firmographics
Name
AEYE Health
Legal name
AEYE Health, Inc.
Website
https://aeyehealth.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
AEYE Health is a US digital health company that markets AEYE-DS, an FDA-cleared fully autonomous AI for diabetic retinopathy screening using a single retinal image per eye, deployed via SaaS subscription into primary care, endocrinology, teleretinal, pharmacy, and rural clinic settings.
Ownership category
akta.pro rank

AEYE Health industry classification

Industry
Product category
AI Medical Diagnostics
NAICS
Diagnostic Imaging Centers (621512)
SIC
Surgical & Medical Instruments & Apparatus (3841), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAHAJAB
Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAKAKAN
Ocular Imaging & Diagnostic Testing Centers

Keywords

  • AI retinal screening
  • Diabetic retinopathy detection
  • Autonomous diagnostic AI
  • Medical imaging software
  • Clinical decision support

Where AEYE Health is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices2 records

Markets served

AEYE Health business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure, Supply Chain

Revenue model

  1. AEYE-DS SaaS Subscription: All-inclusive Software as a Service (SaaS) subscription model requiring no upfront capital investment. The subscription covers the indicated retinal camera, EHR integration, and software updates with no hidden charges. Two subscription tiers: Limited (tailored for practices with specific/predictable patient volumes) and Unlimited (for high-volume health systems maximizing screening reach without per-patient constraints). Revenue is generated through recurring subscription fees billed on a per-encounter or tiered basis, complemented by CPT 92229 reimbursements retained entirely by the practice.
  2. CPT 92229 Reimbursement: Autonomous AI retinal analysis is billed under CPT 92229, a dedicated point-of-care autonomous retinal analysis code fully reimbursable across Medicare, Medicaid, and private insurance. For 2026, Medicare national average reimbursement is approximately $50 per exam; private insurers frequently reimburse up to $100 per exam. Practices retain 100% of reimbursement when billing AEYE-DS under CPT 92229 because the AI performs the diagnostic analysis autonomously, eliminating the need for specialist over-reads or fee-splitting.

Pricing tiers

ModelBillingPrice
SubscriptionMulti-year contractLimited Subscription - for practices with specific or predictable patient volumes
SubscriptionMulti-year contractUnlimited Subscription - for high-volume health systems
Transaction based/ take ratePay-as-you-goCPT 92229 Reimbursement (per exam)

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

AEYE Health product offering

Product offering

Core offering

AEYE Health develops and sells FDA-cleared autonomous AI software (AEYE-DS) that analyzes retinal fundus images to screen for diabetic retinopathy at the point of care, delivering diagnostic results in under one minute without requiring specialist interpretation. The all-inclusive SaaS subscription bundles the AI software, compatible retinal cameras (portable Optomed Aurora or tabletop Topcon NW400), and EHR/EMR integration, enabling primary care providers, endocrinologists, health systems, and pharmacies to perform reimbursable DR screening (CPT 92229) during routine visits. The investigational AEYE-X platform extends the technology to comprehensive screening for over 100 ocular and systemic conditions from a single retinal image.

Product overview

AEYE Health offers a dual-product portfolio centered on AI-powered retinal imaging diagnostics. AEYE-DS is the FDA-cleared core product for autonomous diabetic retinopathy screening, available in two configurations: portable (Optomed Aurora) and tabletop (Topcon NW400). AEYE-X is an investigational comprehensive screening platform extending the technology to detect and predict over 100 systemic and ocular conditions from retinal images. Both products use deep learning to analyze retinal images, deliver results in under one minute at point of care, and require only one image per eye with no dilation.

Differentiator

Problem solved

Functional benefit

Brands

  • AEYE-DS: FDA-cleared autonomous AI diagnostic screening solution for diabetic retinopathy screening using portable and tabletop retinal cameras.
  • AEYE-X
  • Aurora AEYE

Products and services

  • AEYE-DS FDA-cleared fully autonomous AI diagnostic screening solution for point-of-care detection of more-than-mild diabetic retinopathy (mtmDR) in adults diagnosed with diabetes. Uses a single non-mydriatic retinal image per eye with no dilation required, available in portable handheld (Optomed Aurora, 92-93% sensitivity, 89-94% specificity) and tabletop (Topcon NW400, 93% sensitivity, 91% specificity) configurations. Delivers diagnostic results in under one minute with AI processing under 5 seconds, achieves >99% imageability, requires no physician interpretation, and is reimbursable under CPT 92229. Integrates with Epic and other EHRs for automated ordering, result delivery, billing, and care gap reporting.
  • AEYE-X Investigational AI-based comprehensive screening platform for detecting or predicting over 100 conditions from single retinal images per eye. Analyzes ocular diseases (diabetic retinopathy, glaucoma, AMD, retinal occlusions, cataract, diabetic macular edema), systemic health (cardiovascular disease, hypertension, diabetes, CKD), cognitive health (dementia risk), and vision/refractive assessment using deep learning algorithms. Camera-agnostic, delivers results in under one minute. Includes predictive blood pressure estimation capability validated against the UK Biobank. Not sold in the US; available for investigational use only.

Companies that use AEYE Health

Customer profile

Named customers2 records

Segments5 records

Ideal customer profiles4 records

AEYE Health technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability5 records

Feature6 records

AEYE Health partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • Epic SystemscoreTechnology or Integration · 1 January 2026AEYE Health expanded its nationwide integration of AEYE-DS with Epic Systems' electronic medical record platform, enabling healthcare providers to order and receive diabetic retinopathy screening results in under 1 minute directly within their existing Epic clinical workflows. The integration supports automated billing under CPT 92229, care gap reporting, and automated referral triggers for positive cases. This partnership is described as one of the first-ever AI-specific reimbursement integrations in healthcare.
  • Ford MedicalcoreChannel Partner/ Reseller/ Distributor · 1 July 2025AEYE Health partnered with Ford Medical in July 2025 to distribute AI-based retinal imaging screening solutions across US pharmacies. This partnership enables pharmacy-based point-of-care diabetic retinopathy screening, extending AEYE Health's reach into community retail health settings and expanding access to screening for underserved populations.
  • Topcon HealthcarecoreTechnology or Integration · 1 April 2025AEYE Health partnered with Topcon Healthcare to integrate its autonomous diabetic retinopathy screening AI into the Topcon NW500 fundus camera (announced April 2025). This enables the Topcon NW500 to deliver AEYE-DS's autonomous AI diagnostic results at the point of care, expanding the hardware ecosystem compatible with AEYE-DS.
  • OptomedcoreStrategic or Co-development Partner · 1 June 2024AEYE Health and Optomed partnered to launch Aurora AEYE, the first FDA-cleared portable AI-powered diabetic retinopathy screening solution providing on-the-spot diagnosis. Optomed provides the Aurora handheld retinal camera; AEYE Health provides the autonomous AI diagnostic software. This partnership resulted in the first-ever FDA clearance for a fully autonomous AI for portable diabetic retinopathy screening (May 2024).

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

AEYE Health competitors and assessment

Company assessment

Direct peers

  • Digital Diagnostics: Digital Diagnostics developed IDx-DR, the first FDA-cleared fully autonomous AI for diabetic retinopathy screening. It is the most direct head-to-head competitor to AEYE-DS in US primary care, sharing the autonomous, non-mydriatic, single-image-per-eye workflow and targeting the same CPT 92229 reimbursement code.
  • Eyenovia: Eyenovia acquired the EyeArt AI-based diabetic retinopathy screening system, one of the most widely deployed autonomous DR screening platforms globally. EyeArt competes with AEYE-DS for primary care, endocrinology, and teleretinal screening contracts, and Eyenovia's deeper commercial footprint makes it a key benchmark for AEYE's enterprise sales motion.
  • Intelligent Retinal Imaging Systems (IRIS): IRIS operates a teleretinal screening service used by health systems and primary care clinics, and integrated AEYE-DS into its platform in 2023. IRIS is both a distribution partner and a competitor whose legacy human-reader workflow is being displaced by autonomous AI, making it a closely comparable teleretinal service peer.

Broad incumbents

  • Topcon Healthcare: Topcon is a global ophthalmic device incumbent whose NW400 and NW500 fundus cameras are integrated with AEYE-DS. As a hardware partner, Topcon is a route to market, but it also develops its own screening software ecosystem and Harmony RS (retinal data management), making it both a collaborator and a potential competitor in integrated DR screening.
  • Nanox (Zebra Medical Vision): Nanox acquired Zebra Medical Vision, an AI medical imaging company that analyzes radiology images to detect multiple conditions. While focused on radiology rather than retinal screening, Zebra/Nanox is a comparable medical imaging AI platform peer with a similar multi-condition, AI-driven diagnostic ambition to AEYE-X.
  • VoxelCloud: VoxelCloud is a medical imaging AI company providing diagnostic AI solutions across ophthalmology, radiology, and pathology. It is comparable to AEYE Health as a medical imaging AI vendor, with overlap in ophthalmic disease detection from imaging data, and serves as a broad-incumbent reference point for AI clinical screening scale-up.

Emerging players

  • Optomed: Optomed is the maker of the Aurora handheld retinal camera, which AEYE-DS is integrated with to produce the only FDA-cleared portable autonomous DR screening solution. Optomed also sells its own AI screening software and competes in the portable fundus camera category, making it a strategic partner with overlapping commercial interests.
  • RetinAI Medical (Ikerian): RetinAI Medical (now Ikerian) develops AI platforms for retinal image analysis covering diabetic retinopathy, AMD, and glaucoma, with both pharma research and clinical screening use cases. It is an emerging peer to AEYE-X's multi-condition screening thesis and competes in the broader ophthalmic AI analytics category.
  • Sight Diagnostics: Sight Diagnostics applies computer vision and AI to blood and retinal analysis, with FDA-cleared products for point-of-care diagnostics. Its combination of AI imaging diagnostics and decentralised point-of-care deployment is conceptually similar to AEYE's portable, single-image autonomous screening model.

Others

  • Arterys: Arterys (now Tempus) provides cloud-native AI medical imaging platforms deployed in clinical workflows. It is an adjacent AI imaging infrastructure peer rather than a direct competitor, but is relevant context for AEYE's positioning of AI diagnostics integrated directly into clinical workflow and reporting.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

AEYE Health social profiles

Digital presence

AEYE Health compliance and trust

Trust signal

Compliance1 record

AEYE Health financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AEYE Health leadership team

Management profile

Number of profiles

Profiles11 records

AEYE Health funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AEYE Health M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AEYE Health

What does AEYE Health do?

AEYE Health develops and sells FDA-cleared autonomous AI software (AEYE-DS) that analyzes retinal fundus images to screen for diabetic retinopathy at the point of care, delivering diagnostic results in under one minute without requiring specialist interpretation. The all-inclusive SaaS subscription bundles the AI software, compatible retinal cameras (portable Optomed Aurora or tabletop Topcon NW400), and EHR/EMR integration, enabling primary care providers, endocrinologists, health systems, and pharmacies to perform reimbursable DR screening (CPT 92229) during routine visits. The investigational AEYE-X platform extends the technology to comprehensive screening for over 100 ocular and systemic conditions from a single retinal image.

Is AEYE Health a public or private company?

AEYE Health is a private company. It is classified as venture growth investor backed and is currently operating.

When was AEYE Health founded?

AEYE Health was founded in 2019. It employs 11 to 50 people.

Where is AEYE Health based?

AEYE Health is headquartered in New York, United States, in the North America region.

How does AEYE Health make money?

Two revenue lines are on record. AEYE-DS SaaS Subscription is the primary driver. The others are CPT 92229 Reimbursement.

Who are AEYE Health's main competitors?

Direct peers on record are Digital Diagnostics, Eyenovia and Intelligent Retinal Imaging Systems (IRIS). Broad incumbents are Topcon Healthcare, Nanox (Zebra Medical Vision) and VoxelCloud. Emerging players are Optomed, RetinAI Medical (Ikerian) and Sight Diagnostics. Arterys is listed as an others.

Does AEYE Health have an API?

Yes. AEYE-DS features API integration to send exams and receive results, enabling teleretinal screening services to process exams programmatically. The API is scalable to process any volume of exams needed.

What industry is AEYE Health in?

AEYE Health's product category is AI Medical Diagnostics. Its primary akta.pro industry code is HLAHAJAB, Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography), with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 621512 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Jerusalem PostIsraeli-US AEYE Health wins award for new AI technology preventing blindnessAEYE Health's AEYE-DS AI diagnostic tool for diabetic retinopathy screening won the 2026 Prix Galien USA Award for Best Digital Health Solution. The FDA-cleared, autonomous screening system aims to make sight-saving eye exams accessible, and the company is expanding across the United States.PR NewswireAEYE Health and Dr. Zack Dvey-Aharon Win Prestigious 2026 Prix Galien USA Award for Groundbreaking AI Technology Preventing BlindnessAEYE Health's FDA-cleared AI diagnostic AEYE-DS won the 2026 Prix Galien USA Award for Best Digital Health Solution. The autonomous diabetic eye exam requires no physician interpretation and was validated in three phase-III trials with over 1,200 patients. The company is advancing AEYE-X, a next-generation oculomics platform.PR NewswireAEYE-DS Clinical Trials Published: First Fully Autonomous Diabetic Retinopathy Screening Technology Across Portable and Tabletop Devices Demonstrates 99% Imageability, One-Image-per-Eye Workflow, andAEYE Health published peer-reviewed trial results for its FDA-cleared AEYE-DS AI screening for diabetic retinopathy, involving over 1,200 patients across three studies. The solution achieves >99% imageability and requires only one image per eye, with sensitivity of 92-93% for portable and 93% for tabletop devices.PR NewswireNew Real-World Data Shows AEYE-DS Autonomous AI Achieving a 96% Success Rate (Imageability) Without Dilation in a High-Traffic Endocrinology ClinicAEYE Health published a study showing its AEYE-DS system achieved 95.7% imageability without dilation in 256 diabetes patients at Sheba Medical Center. The autonomous AI, used with a Topcon NW500 camera, required only one hour of training for a novice operator. The study provides a blueprint for scaling point-of-care diabetic retinopathy screening.Straits ResearchRetinal Imaging Devices Market Size, Top Share, DemandThe global retinal imaging devices market was valued at USD 4.01 billion in 2025 and is projected to grow to USD 7.80 billion by 2034, reflecting a CAGR of 7.71% during the forecast period, driven by rising diabetes prevalence, increasing vision disorders, and technological advancements in AI-based diagnostics and teleophthalmology. North America led the market with a 37.15% share in 2025, while Asia Pacific is expected to be the fastest-growing region with a projected CAGR of 9.71%. Key recent developments include Optomed's January 2026 partnership with Aireen a.s. for AI-driven retinal image analysis, OptainHealth's November 2025 acquisition of EyePACS, and AEYE Health's July 2025 partnership with Ford Medical for distributing AI-based retinal imaging screening solutions across US pharmacies.GlobeNewswireU.S. AI-driven Diabetic Retinopathy Screening Market Trends 2026-2033 Featuring Profiles of Eyenuk, Digital Diagnostics, AEYE Health, Optomed, IRIS and Other Key PlayersA market research report projects the U.S. AI-driven diabetic retinopathy screening market to grow from USD 190.01 million in 2025 to USD 881.74 million by 2033, representing a compound annual growth rate of 21.18%. The report attributes this growth to rising diabetes prevalence—affecting 38.4 million U.S. residents according to CDC data—favorable Medicare reimbursement via CPT code 92229 for autonomous AI diagnostics, and limited access to ophthalmologists in primary care settings. Key market players profiled include Eyenuk, Digital Diagnostics, AEYE Health, Optomed, IRIS, RETINA-AI Health, iCare, RetinaRisk, and BeamMed, while Mount Sinai's 2023 launch of its Center for Ophthalmic Artificial Intelligence is cited as a notable industry development.GlobeNewswireU.S. AI-driven Diabetic Retinopathy Screening Market Trends 2026-2033 Featuring Profiles of Eyenuk, Digital Diagnostics, AEYE Health, Optomed, IRIS and Other Key PlayersThe U.S. AI-driven diabetic retinopathy screening market is expected to grow from USD 190.01 million in 2025 to USD 881.74 million by 2033, driven by increasing diabetes prevalence and technological adoption. The growth is facilitated by policy changes such as new reimbursement codes, enabling primary care providers to deploy autonomous AI diagnostic systems. Key players include Eyenuk, Digital Diagnostics, AEYE Health, Optomed, and IRIS.Market ScoopAI In Ophthalmology MarketThe global AI in ophthalmology market is projected to grow from US$291.5 million in 2025 to US$7,462.1 million by 2035, representing a compound annual growth rate of 38.3%, with North America leading at a 52.4% market share. Key applications include disease detection and monitoring (61.8% share), with machine learning (36.4%) and cloud-based deployment (84.8%) as dominant technology and deployment modes respectively. Recent developments include Toku's validation study with Mayo Clinic for CLAiR cardiovascular risk assessment technology (January 2026), AEYE Health's partnership with Topcon Healthcare to integrate autonomous diabetic retinopathy screening AI into the Topcon NW500 fundus camera (April 2025), and Digital Diagnostics' achievement of 1 million clinical screenings with its LumineticsCore AI system in the US (August 2025).PR NewswireAEYE Health's AI Retinal Imaging Redefines Non-Invasive Blood Pressure MonitoringAEYE Health announced publication of a landmark study in BMJ Innovations demonstrating that its deep learning technology can estimate both systolic and diastolic blood pressure from a single non-mydriatic retinal image with accuracy matching or surpassing traditional arm cuff measurements. The study, validated using over 100,000 patient images from the UK Biobank, showed that retinal microvasculature provides a more stable assessment of chronic hypertensive burden compared to momentary cuff snapshots. The research marks a milestone for AEYE-X, AEYE Health's comprehensive AI screening platform designed to leverage retinal images for detecting multiple medical indications beyond eye disease.Eyes On EyecareAEYE Health broadens Epic EMR integration for AI eye screeningAEYE Health announced a nationwide expansion of its FDA-cleared AI-based diabetic retinopathy screening technology integration with Epic Systems' electronic medical record platform. Healthcare providers using Epic can now order and receive screening results in under 1 minute directly within their existing clinical workflows, enabling point-of-care diabetic eye exams without physician interpretation. The AEYE-DS system uses a portable camera to capture retinal images and achieves over 90% accuracy for sensitivity and specificity, with automated billing and care gap reporting supported through the integration.